Role of Colesevelam in Combination Lipid-Lowering Therapy

Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis – guidelines vs. reality

(2014) Maria Bożentowicz-Wikarek et al.   Pharmacological Reports

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia

(2013) Mukul Sharma et al.   ANNALS OF INTERNAL MEDICINE

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

(2013) Ishak Mansi et al.   JAMA Internal Medicine

Statins and risk of treated incident diabetes in a primary care population

(2012) Nur Lisa Zaharan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Statins and Risk of Diabetes: An analysis of electronic medical records to evaluate possible bias due to differential survival

(2012) G. Danaei et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy

(2012) David D. Waters et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Colesevelam Plus Rosuvastatin 5 mg/Day Versus Rosuvastatin 10 mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose

(2012) Matilda Florentin et al.   Metabolic Syndrome and Related Disorders

Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project

(2012) Nina Rautio et al.   BMJ Open

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)

(2011) Jennifer G. Robinson et al.   Journal of Clinical Lipidology

Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy

(2011) Amy Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12-week, multicenter, randomized, double-blind, controlled trial

(2010) Roeland Huijgen et al.   CLINICAL THERAPEUTICS

Statin myopathy: a review of recent progress

(2010) Andrew L Mammen et al.   CURRENT OPINION IN RHEUMATOLOGY

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

(2010) Komelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Statin-Associated Muscle-Related Adverse Effects: A Case Series of 354 Patients

(2010) Stephanie Cham et al.   PHARMACOTHERAPY

Statin Adverse Effects

(2009) Beatrice A Golomb et al.   American Journal of Cardiovascular Drugs

Combined therapy in the treatment of dyslipidemia

(2009) Željko Reiner   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

(2009) Karen S. Brown et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

(2009) Kornelia Kotseva et al.   LANCET

Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis

(2009) Ishwarlal Jialal et al.   Metabolic Syndrome and Related Disorders

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy

(2008) Ronald B. Goldberg   ARCHIVES OF INTERNAL MEDICINE

Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin

(2008) Harold E. Bays et al.   ARCHIVES OF INTERNAL MEDICINE

Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

(2008) V. A. Fonseca et al.   DIABETES CARE

Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials

(2008) A. Pandor et al.   JOURNAL OF INTERNAL MEDICINE